Athersys $ATHX announced on Wednesday that FDA agreed under a Special Protocol Assessment (SPA) for the design and planned evaluation of a Phase 3 clinical trial of MultiStem cell therapy product, intended to cure ischemic stroke. The outcome from the Phase 3 trial termed as, �MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2� (MASTERS-2), along with other available clinical data, would provide the basis of the regulatory package to be submitted for marketing approval. Shares soared in early-trading hours.